Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



New data shows that intensive treatment of diabetes may lower coexistent hypertension and delay renal dialysis by up to 20 years

06 Apr 04

DailyUpdates 6th April: According to WHO, there are some 130 million diagnosed diabetics in the world and the long term consequences of diabetes such as diabetic nephropathy are becoming increasingly frequent and unmet components of diabetes care. In a recent study Glasgow Royal Infirmary researchers report that intensive treatment slowed progression of renal disease within 2 years in patients with established diabetic nephropathy and predict that this approach may delay the onset of dialysis b

Links between obesity/diabetes & Alzheimer disease: Diet-induced insulin resistance shown to increase CNS beta-amyloid levels and worsens cognition in a model of Alzheimer disease

05 Apr 04

DailyUpdates 5th April: There is growing evidence of a link between type-2 diabetes/obesity and Alzheimer disease. Researchers now report that diet-induced insulin resistance increases beta amyloid generation, amyloid plaque burden in the brain and behavioural impairment in a model of Alzheimer disease.

Type 2 diabetes as a risk factor for Alzheimer's disease - defective insulin-degrading enzyme as an etiological link?

02 Apr 04

DailyUpdates 2nd April: There is growing evidence that type-2 diabetes is a risk factor for Alzheimer disease. In their April American Journal of Pathology article Brigham and Women's Hospital researchers add further evidence to support defects in insulin-degrading enzyme activity as a potential cause of this phenomenon. This and similar data argues for the development of cross-indication treatments of type-2 diabetes and Alzheimer disease and GSK-3 inhibitors may fit the bill.

GREES publish new recommendations on the clinical development of disease modifying osteoarthritis drugs (DMOADs)

01 Apr 04

DailyUpdates 1st April: Osteoarthritis is the most common form of arthritis and is estimated to affect over 73 million people in the seven major pharmaceutical markets. Disease modifying osteoarthritis drugs (DMOADs) currently represent the ‘holy grail’ in the treatment of osteoarthritis. The Group for the Respect of Ethics and Excellence in Science (GREES) have now published recommendations on the clinical development of DMOADs.

Merck & Co develop new leads for the treatment of bipolar disorder through the development of a new HTS assay of inositol monophosphatase inhibitors

31 Mar 04

DailyUpdates 31st March: Bipolar disorder affects over 2 million people in the US alone. Lithium, which inhibits inositol monophosphatase, has long been a first line mood stabilizer used in the treatment of this condition. Merck & Co have now developed a new cell-based HTS assay to identify novel inositol monophosphatase inhibitors which will hopefully lead to improved treatments of bipolar disorder.

Sulfonylureas vs thiazolidinediones for the prevention of diabetic nephropathy

30 Mar 04

DailyUpdates 30th March: According to WHO, there are some 130 million diagnosed diabetics in the world and the long term consequences of diabetes such as diabetic nephropathy are becoming increasingly frequent and unmet components of diabetes care. Intensive glycemic control prevents or retards microalbuminuria, an early sign of nephropathy in patients with type 2 diabetes and in a recent study Japanese researchers compare two different classes of oral antidiabetic drugs with respect to their e

New data published on KW-7158, a novel treatment of overactive bladder

29 Mar 04

Overactive bladder, a condition associated with a variety of other pathologies affects over 17 million Americans and costs the US over $12 billion per year. Current treatments focus on the muscarinic receptor antagonists such as tolterodine and oxybutanin with further examples from this class expected on the market. Therapeutics from novel pharmacological classes are expected to offer further improvements and in an upcoming edition of the Journal of Pharmacology & Experimental Therapeutics Uni

Naked Ambition

28 Mar 04

The presence of Arthur Dent's in pyjamas throughout the Hitch Hiker's Guide to the Galaxy, in a series of increasingly surreal encounters, acts as a constant reminder to the reader that no matter what
Daniel Judge

All in the name of research

25 Mar 04

Andrew Curl from the ABPI explains more about the industry's ability to innovate and provide world-beating medicines.
Claire Richland

Finding the Next Asian Pharma Sensation

19 Mar 04

Japan has always been considered the technology pioneer of Asia, however, in recent years a number of other countries in this region have placed significant emphasis on industrial and technological performance in order to improve their own world position. One industry that is developing rapidly in the region is the pharmaceutical industry.
Dr Faiz Kermani and Dr Rebecca Gittins

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.